PDCD1LG2 and neoplasm: The most important peripheral checkpoint inhibitor pathway exploited by tumour cells within the TME from a clinical perspective to date, is the interaction between the PD-1 receptor on T-cells with its ligands PD-L1 and PD-L2 on tumour cells [175].